Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash from Financing Activities (2017 - 2026)

Denali Therapeutics has reported Cash from Financing Activities over the past 9 years, most recently at $192.1 million for Q4 2025.

  • Quarterly Cash from Financing Activities rose 4709.72% to $192.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $189.2 million through Dec 2025, down 60.93% year-over-year, with the annual reading at $189.2 million for FY2025, 60.93% down from the prior year.
  • Cash from Financing Activities was $192.1 million for Q4 2025 at Denali Therapeutics, up from -$778000.0 in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $500.3 million in Q1 2024 and troughed at -$18.6 million in Q3 2024.
  • The 5-year median for Cash from Financing Activities is $4.1 million (2021), against an average of $51.1 million.
  • The largest YoY upside for Cash from Financing Activities was 31089.21% in 2024 against a maximum downside of 844.74% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $5.2 million in 2021, then surged by 5698.2% to $299.7 million in 2022, then tumbled by 98.43% to $4.7 million in 2023, then tumbled by 188.59% to -$4.2 million in 2024, then skyrocketed by 4709.72% to $192.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Cash from Financing Activities are $192.1 million (Q4 2025), -$778000.0 (Q3 2025), and $1.6 million (Q2 2025).